BTIG Research initiated coverage of Apyx Medical with a rating of Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2024 | Neutral | BTIG Research | |
| 7/14/2023 | $8.00 | Overweight | Stephens |
| 5/20/2022 | $12.00 | Buy | Lake Street |
| 8/13/2021 | $12.00 → $14.00 | Market Outperform | JMP Securities |
BTIG Research initiated coverage of Apyx Medical with a rating of Neutral
Stephens initiated coverage of Apyx Medical with a rating of Overweight and set a new price target of $8.00
Lake Street initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $12.00
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
10-Q - Apyx Medical Corp (0000719135) (Filer)
424B5 - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will provide Renuvion treatments to people who can most benefit from this advanced medical technology. Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best from the inside out by targeting loose skin directly at the source. As the only device that is FDA-cleared for contracting subcutaneous tissue, Renuvion provides people with a proven solu
Gainers Longeveron (NASDAQ:LGVN) stock rose 30.9% to $2.37 during Thursday's pre-market session. The company's market cap stands at $15.0 million. JanOne (NASDAQ:JAN) stock rose 26.07% to $3.24. The company's market cap stands at $37.8 million. Bionomics (NASDAQ:BNOX) shares increased by 21.62% to $0.85. The market value of their outstanding shares is at $9.0 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 20.74% to $1.63. The company's market cap stands at $11.0 million. Holdco Nuvo Group DG (NASDAQ:NUVO) stock rose 20.22% to $1.84. The company's market cap stands at $61.2 million. Vivani Medical (NASDAQ:VANI) stock rose 15.9% to $1.89. The market value of their outstandin
CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton NY Times Square Hotel, New York, NYFormat: 1x1 Meetings To request a meeting with Apyx, investors should contact their Craig Hallum representative. About Apyx Medical Corporation: Apyx Medical Corporation is an advanced energy
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the
Strengthened balance sheet with a common stock registered direct offering with gross proceeds of approximately $7.0 million; and amended revenue covenants for the Company's credit agreement with PerceptiveAnnounces cost savings restructuring program to better focus, optimize and streamline operations, including a nearly 25% reduction in U.S. workforce Announces 9% overall growth in single-use handpiece revenue and 15% growth in the U.S.Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platfor
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. Management will host a conference call at 8:00 a.m. Eastern Time on November 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024 Financial Summary: Total revenue of $12.1 million, a decrease of 10% year-over-year. Advanced Energy revenue of $9.8 million, a decrease of 17% year-over-year. OEM revenue of $2.4 million, an increase of 29% year-over-year. Net loss attributable to stockholders of $6.6 million, an increase of $5.6 million, or 5
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th. Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 888-645-4404 (or 862-298-0702 for international callers) and provide access code 13747529. Participants should ask for the Apyx Medical Corporation Call.
SC 13G - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13D/A - Apyx Medical Corp (0000719135) (Subject)